No results were found for your search. Please adjust your search term or broaden your search criteria.
Still can't find what you are looking for? We can prepare Custom Research for you.
Bromodomain Containing Protein 3 (BRD3) is a protein that plays a role in the regulation of gene expression. It is a member of the bromodomain and extra-terminal (BET) family of proteins, which are involved in the regulation of chromatin structure and gene expression. BRD3 has been implicated in the development and progression of several types of cancer, including breast, lung, and prostate cancer.
In oncology, BRD3 has been studied as a potential target for drug development. Several small molecule inhibitors of BRD3 have been developed, and are being evaluated in clinical trials for the treatment of various types of cancer. These inhibitors are designed to block the activity of BRD3, thereby preventing the expression of genes that are involved in cancer progression.
Several companies are involved in the development of BRD3 inhibitors for oncology. These include Merck, AstraZeneca, Novartis, Pfizer, and GlaxoSmithKline. These companies are researching and developing BRD3 inhibitors for the treatment of various types of cancer. Show Less Read more
